Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 May;39(5):180-4.
doi: 10.4070/kcj.2009.39.5.180. Epub 2009 May 28.

The effect of telmisartan on endothelial function and arterial stiffness in patients with essential hypertension

An Doc Jung  1 , Weon Kim, Sang Hyun Park, Jeong Su Park, Sang Cheol Cho, Sung Bum Hong, Sun Ho Hwang, Wan Kim
Affiliations

The effect of telmisartan on endothelial function and arterial stiffness in patients with essential hypertension

An Doc Jung et al. Korean Circ J. 2009 May.

Abstract

Background and objectives: Several studies have shown that angiotensin II receptor blockers (ARBs) improve endothelial function and arterial stiffness. Telmisartan is a highly selective ARB that activates peroxisome proliferator-activated receptor gamma (PPARgamma). The purpose of this study was to evaluate the effects of telmisartan, such as endothelial function, arterial stiffness, and insulin sensitivity, in patients with essential hypertension.

Subjects and methods: Thirty-nine patients with essential hypertension were administered telmisartan (80 mg once daily) using an open-labeled and prospective protocol. The patients were examined before and 8 weeks after treatment to assess changes in flow mediated-vasodilation (FMD), pulse wave velocity (PWV), quantitative insulin-sensitivity check index (QUICKI), homeostasis model assessment (HOMA), and adiponection.

Results: The systolic and diastolic blood pressure (BP) decreased from 153+/-15 mmHg and 90+/-13 mmHg to 137+/-16 mmHg and 84+/-10 mmHg after telmisartan treatment, respectively (p<0.01). Telmisartan therapy increased the FMD from 7.6+/-3.5 to 9.0+/-2.8% (p<0.01). The following parameters of arterial stiffness were significantly improved after telmisartan therapy: brachial-ankle pulse wave velocity (baPWV), from 17.2+/-3.1 to 15.9+/-2.6 m/sec; heart-carotid PWV (hcPWV), from 9.7+/-1.8 to 9.0+/-1.9 m/sec; and heart-femoral PWV (hfPWV), from 11.3+/-1.9 to 10.7+/-1.9 m/sec (p<0.01). There were no changes in QUICKI, the HOMA level, and plasma adiponectin (p=NS).

Conclusion: These results suggest that telmisartan is effective in improving endothelial function and arterial stiffness in patients with essential hypertension.

Keywords: Angiotensin II type 1 receptor blockers; Arteriosclerosis; Endothelium, vascular.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Effects of telmisartan on systolic and diastolic blood pressure (BP). P<0.05 vs. baseline value.
Fig. 2
Fig. 2
Change of flow mediated-dilation (FMD) at baseline and 8 weeks after telmisartan treatment. P<0.01 vs. baseline value.
See this image and copyright information in PMC

References

    1. Han SH, Quon MJ, Koh KK. Reciprocal relationships between abnormal metabolic parameters and endothelial dysfunction. Curr Opin Lipidol. 2007;18:58–65. - PubMed
    1. On YK, Chung WY, Kim YS, et al. Improvement in endothelial function by angiotensin-converting enzyme inhibition and vitamin C in essential hypertension. Korean Circ J. 2001;31:411–419.
    1. Chalmers J, MacMahon S, Mancia G, et al. 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension: guidelines subcommittee. Clin Exp Hypertens. 1999;21:1009–1060. - PubMed
    1. Blacher J, Asmar R, Djane S, London GM, Safar ME. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension. 1999;33:1111–1117. - PubMed
    1. Safar ME, Toto-Moukouo JJ, Bouthier JA, et al. Arterial dynamics, cardiac hypertrophy, and antihypertensive treatment. Circulation. 1987;75:I156–I161. - PubMed